{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:03Z","timestamp":1791272343363,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00277-011-1212-5","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T04:27:16Z","timestamp":1301545636000},"page":"1265-1275","source":"Crossref","is-referenced-by-count":41,"title":["A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes"],"prefix":"10.1007","volume":"90","author":[{"given":"Emel B.","family":"Gencer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali U.","family":"Ural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferit","family":"Avcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"1212_CR1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2001.1.87","volume":"1","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM (2001) Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 1:87\u2013112","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1212_CR2","doi-asserted-by":"crossref","unstructured":"Shah NP (2007) Medical Management of CML. Hematology 371\u2013375","DOI":"10.1182\/asheducation-2007.1.371"},{"key":"1212_CR3","first-page":"161","volume":"4","author":"E Koca","year":"2005","unstructured":"Koca E, Haznedaroglu IC (2005) Imatinib mesylate and the management of chronic myeloid Leukemia (CML). Turk J Haematol 4:161\u2013172","journal-title":"Turk J Haematol"},{"key":"1212_CR4","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MWN Deininger","year":"2000","unstructured":"Deininger MWN, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"1212_CR5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"1212_CR6","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V97.8.2406","volume":"97","author":"RC Zhao","year":"2001","unstructured":"Zhao RC, Jiang Y, Verfaillie CM (2001) A model of human p210(bcr\/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR\/ABL-containing retroviral vector. Blood 97:2406\u20132412","journal-title":"Blood"},{"key":"1212_CR7","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1073\/pnas.0607006103","volume":"103","author":"F Michor","year":"2006","unstructured":"Michor F, Iwasa Y, Nowak MA (2006) The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. PNAS 103:14931\u201314934","journal-title":"PNAS"},{"key":"1212_CR8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935\u2013942","journal-title":"J Clin Oncol"},{"key":"1212_CR9","doi-asserted-by":"crossref","first-page":"10922","DOI":"10.1074\/jbc.M610157200","volume":"282","author":"Y Baran","year":"2007","unstructured":"Baran Y, Salas A, Senkal CE, Bielawski J, Gunduz U, Obeid LM, Ogretmen B (2007) Alterations of human longevity assurance gene 1 (LASS1)\/sphingosine kinase-1-dependent ceramide generation and metabolism involve in the regulation of imatinib-induced apoptosis and resistance in K562 human chronic myeloid leukemia (CML) cells. J Biol Chem 282:10922\u201310934","journal-title":"J Biol Chem"},{"key":"1212_CR10","first-page":"281","volume":"5","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG, Tsimberidou AM (2009) Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 5:281\u2013289","journal-title":"Ther Clin Risk Manag"},{"key":"1212_CR11","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FYF, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates \u0131ts \u0131nhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797","journal-title":"Cancer Res"},{"key":"1212_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","volume":"184","author":"M Lindauer","year":"2010","unstructured":"Lindauer M, Hochhaus A (2010) Dasatinib. Recent Results Cancer Res 184:83\u2013102","journal-title":"Recent Results Cancer Res"},{"key":"1212_CR13","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1158\/0008-5472.CAN-05-4620","volume":"66","author":"L Song","year":"2006","unstructured":"Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542\u20135548","journal-title":"Cancer Res"},{"key":"1212_CR14","doi-asserted-by":"crossref","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-05-0757","volume":"11","author":"FM Johnson","year":"2005","unstructured":"Johnson FM, Saigal B, Talpaz M, Donato NJ (2005) Dasatinib (BMS-354825) tyrosine kinase \u0131nhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924\u20136932","journal-title":"Clin Cancer Res"},{"key":"1212_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","volume":"105","author":"RS Finn","year":"2007","unstructured":"Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ (2007) Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105:319\u2013326","journal-title":"Breast Cancer Res Treat"},{"key":"1212_CR16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canlet.2009.03.035","volume":"283","author":"J Nautiyal","year":"2009","unstructured":"Nautiyal J, Majumder P, Patel BB, Lee FY, Majumdar APN (2009) Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett 283:143\u2013151","journal-title":"Cancer Lett"},{"key":"1212_CR17","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1016\/j.febslet.2006.08.052","volume":"580","author":"B Ogretmen","year":"2006","unstructured":"Ogretmen B (2006) Sphingolipids in cancer: regulation of pathogenesis and therapy. FEBS Lett 580:5467\u20135476","journal-title":"FEBS Lett"},{"key":"1212_CR18","first-page":"604","volume":"4","author":"B Ogretmen","year":"2004","unstructured":"Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nature 4:604\u2013616","journal-title":"Nature"},{"key":"1212_CR19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.canlet.2003.08.034","volume":"206","author":"CP Reynolds","year":"2004","unstructured":"Reynolds CP, Maurer BJ, Kolesnick RN (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206:169\u2013180","journal-title":"Cancer Lett"},{"key":"1212_CR20","doi-asserted-by":"crossref","first-page":"25001","DOI":"10.1074\/jbc.R600010200","volume":"281","author":"Y Pewzner-Jung","year":"2006","unstructured":"Pewzner-Jung Y, Ben-Dor S, Futerman AH (2006) When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J Biol Chem 281:25001\u201325005","journal-title":"J Biol Chem"},{"key":"1212_CR21","doi-asserted-by":"crossref","first-page":"35642","DOI":"10.1074\/jbc.M205211200","volume":"277","author":"K Venkataraman","year":"2002","unstructured":"Venkataraman K, Riebeling C, Bodennec J, Riezman H, Allegood JC, Sullard MC, Merrill AH, Futerman AH (2002) Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J Biol Chem 277:35642\u201335649","journal-title":"J Biol Chem"},{"key":"1212_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1042\/BJ20050291","volume":"390","author":"Y Mizutani","year":"2005","unstructured":"Mizutani Y, Kihara A, Igarashi Y (2005) Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J 390:263\u2013271","journal-title":"Biochem J"},{"key":"1212_CR23","doi-asserted-by":"crossref","first-page":"43452","DOI":"10.1074\/jbc.M307104200","volume":"278","author":"C Riebeling","year":"2003","unstructured":"Riebeling C, Allegood JC, Wang E, Merrill AH, Futerman AH (2003) Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J Biol Chem 278:43452\u201343459","journal-title":"J Biol Chem"},{"key":"1212_CR24","first-page":"905","volume":"16","author":"A Weinmann","year":"2005","unstructured":"Weinmann A, Galle PR, Teufel A (2005) LASS6, an additional member of the longevity assurance gene family. Int J Mol Med 16:905\u2013910","journal-title":"Int J Mol Med"},{"key":"1212_CR25","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1194\/jlr.M500001-JLR200","volume":"46","author":"Z Xu","year":"2005","unstructured":"Xu Z, Zhou J, McCoy DM, Mallampalli RK (2005) LASS5 is the predominant ceramide synthase isoform involved in de novo sphingolipid synthesis in lung epithelia. J Lipid Res 46:1229\u20131238","journal-title":"J Lipid Res"},{"key":"1212_CR26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1388-1981(02)00331-1","volume":"1585","author":"BJ Pettus","year":"2002","unstructured":"Pettus BJ, Chalfant CE, Hannun YA (2002) Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 1585:114\u2013125","journal-title":"Biochim Biophys Acta"},{"key":"1212_CR27","doi-asserted-by":"crossref","first-page":"19530","DOI":"10.1074\/jbc.271.32.19530","volume":"271","author":"Y Lavie","year":"1996","unstructured":"Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC (1996) Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271:19530\u201319536","journal-title":"J Biol Chem"},{"key":"1212_CR28","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.95","volume":"22","author":"E Bonhoure","year":"2008","unstructured":"Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JV, Cuvillier O (2008) Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22:971\u2013979","journal-title":"Leukemia"},{"key":"1212_CR29","first-page":"23","volume":"24","author":"O Piskin","year":"2007","unstructured":"Piskin O, Ozcan MA, Ozsan GH, Ates H, Demirkan F, Alacacioglu I, Undar B (2007) Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines. Turk J Haematol 24:23\u201327","journal-title":"Turk J Haematol"},{"key":"1212_CR30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1535-7163.MCT-06-0558","volume":"6","author":"CE Senkal","year":"2007","unstructured":"Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA, Ogretmen B (2007) Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6:712\u2013722","journal-title":"Mol Cancer Ther"},{"key":"1212_CR31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2741\/e86","volume":"2","author":"L Zhao","year":"2010","unstructured":"Zhao L, Au JL, Wientjes MG (2010) Comparison of methods for evaluating drug-drug interaction. Front Biosci 2:241\u2013249","journal-title":"Front Biosci"},{"key":"1212_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1179\/102453310X12583347009775","volume":"15","author":"HA Ekiz","year":"2010","unstructured":"Ekiz HA, Can G, Baran Y (2010) Nilotinib significantly induces apoptosis in imatinib resistant K562 cells, as effectively as in parental sensitive counterparts. Hematology 15:33\u201338","journal-title":"Hematology"},{"key":"1212_CR33","first-page":"1241","volume":"94","author":"M Kartal","year":"2009","unstructured":"Kartal M, Saydam G, Sahin F, Baran Y (2009) Increasing intracellular generation or accumulation of ceramides increased cytotoxic effects of resveratrol in human K562 chronic myeloid leukemia cells. Haematologica 94:1241","journal-title":"Haematologica"},{"key":"1212_CR34","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O\u2019Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen T, Huang F, Decillis AP, Sawyers CL (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531\u20132541","journal-title":"N Engl J Med"},{"key":"1212_CR35","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","volume":"18","author":"A Olivieri","year":"2007","unstructured":"Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18:vi42\u2013vi46","journal-title":"Ann Oncol"},{"key":"1212_CR36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molmed.2007.06.002","volume":"13","author":"YH Zeidan","year":"2007","unstructured":"Zeidan YH, Hannun YA (2007) Translational aspects of sphingolipid metabolism. Trends Mol Med 13:327\u2013336","journal-title":"Trends Mol Med"},{"key":"1212_CR37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00432-010-0884-x","volume":"137","author":"Z Cakir","year":"2011","unstructured":"Cakir Z, Saydam G, Sahin F, Baran Y (2011) The roles of bioactive sphingolipids in resveratrol-induced apoptosis in Hl60 acute myeloid leukemia cells. J Cancer Res Clin Oncol 137:279\u2013286","journal-title":"J Cancer Res Clin Oncol"},{"key":"1212_CR38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1124\/jpet.106.101949","volume":"317","author":"CE Senkal","year":"2006","unstructured":"Senkal CE, Ponnusamy S, Rossi MJ, Sundararaj K, Szulc Z, Bielawski J, Bielawska A, Meyer M, Cobanoglu B, Koybasi S (2006) Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 317:1188\u20131199","journal-title":"J Pharmacol Exp Ther"},{"key":"1212_CR39","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-04-2329","volume":"65","author":"V Gouaz\u00e9","year":"2005","unstructured":"Gouaz\u00e9 V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC (2005) Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65:3861\u20133867","journal-title":"Cancer Res"},{"key":"1212_CR40","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1074\/jbc.274.2.1140","volume":"274","author":"YY Liu","year":"1999","unstructured":"Liu YY, Han TY, Giuliano AE, Cabot MC (1999) Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274:1140\u20131146","journal-title":"J Biol Chem"},{"key":"1212_CR41","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1369\/jhc.4A6606.2005","volume":"53","author":"KR Johnson","year":"2005","unstructured":"Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA, Obeid LM (2005) Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 53:1159\u20131166","journal-title":"J Histochem Cytochem"},{"key":"1212_CR42","first-page":"5962","volume":"63","author":"KJ French","year":"2003","unstructured":"French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63:5962\u20135969","journal-title":"Cancer Res"},{"key":"1212_CR43","first-page":"1467","volume":"3","author":"GK Schwartz","year":"1997","unstructured":"Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3:1467\u20131472","journal-title":"Clin Cancer Res"},{"key":"1212_CR44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/92.23.1897","volume":"92","author":"BJ Maurer","year":"2000","unstructured":"Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP (2000) Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92:1897\u20131909","journal-title":"J Natl Cancer Inst"},{"key":"1212_CR45","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1124\/jpet.103.062760","volume":"309","author":"AP Struckhoff","year":"2004","unstructured":"Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS (2004) Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 309:523\u2013532","journal-title":"J Pharmacol Exp Ther"},{"key":"1212_CR46","first-page":"1017","volume":"49","author":"KW Crawford","year":"2003","unstructured":"Crawford KW, Bittman R, Chun J, Byun HS, Bowen WD (2003) Novel ceramide analogs display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol Biol 49:1017\u20131023","journal-title":"Cell Mol Biol"},{"key":"1212_CR47","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/cdd.2010.25","volume":"17","author":"MW Harr","year":"2010","unstructured":"Harr MW, Caimi PF, McColl KS, Zhong F, Patel SN, Barr PM, Distelhorst CW (2010) Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia. Cell Death Differ 17:1381\u20131391. doi: 10.1038\/cdd.2010.25","journal-title":"Cell Death Differ"},{"key":"1212_CR48","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","volume":"29","author":"YC Lee","year":"2010","unstructured":"Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, Decrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH (2010) Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29:3196\u20133207. doi: 10.1038\/onc.2010.73","journal-title":"Oncogene"},{"key":"1212_CR49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nchembio.332","volume":"6","author":"J Li","year":"2010","unstructured":"Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, Bennett KL, Gao J, Song L, Eschrich S, Superti-Furga G, Koomen J, Haura EB (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chem Biol 6:291\u2013299","journal-title":"Nature Chem Biol"},{"key":"1212_CR50","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-09-2416","volume":"16","author":"BS Guerrouahen","year":"2010","unstructured":"Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010) Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 16:1149\u20131158","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1212-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1212-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1212-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T19:18:52Z","timestamp":1592421532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1212-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1212-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,1]]}}}